Literature DB >> 21266211

Abnormalities of angiotensin regulation in postural tachycardia syndrome.

Hossam I Mustafa1, Emily M Garland, Italo Biaggioni, Bonnie K Black, William D Dupont, David Robertson, Satish R Raj.   

Abstract

BACKGROUND: Postural tachycardia syndrome (POTS) is a disorder characterized by excessive orthostatic tachycardia and significant functional disability. We previously reported that POTS patients have low blood volume and inappropriately low plasma renin activity (PRA) and aldosterone. In this study, we sought to more fully characterize the renin-angiotensin-aldosterone system (RAAS) to gain a better understanding of the pathophysiology of POTS.
OBJECTIVE: The purpose of this study was to prospectively assess the plasma levels of angiotensin (Ang) peptides and their relationship to other RAAS components in patients with POTS compared with healthy controls.
METHODS: Heart rate, PRA, Ang I, Ang II, Ang (1-7), and aldosterone were measured in POTS patients (n = 38) and healthy controls (n = 13) while they were consuming a sodium-controlled diet.
RESULTS: POTS patients had larger orthostatic increases in heart rate than did controls (52 ± 3 [mean ± SEM] bpm vs 27 ± 6 bpm, P = .001). Plasma Ang II was significantly higher in POTS patients (43 ± 3 pg/mL vs 28 ± 3 pg/mL, P = .006), whereas plasma Ang I and angiotensin 1-7 [Ang-(1-7)] were similar between groups. Despite the twofold increase of Ang II, POTS patients trended to lower PRA levels than did controls (0.9 ± 0.1 ng/mL/h vs 1.6 ± 0.5 ng/mL/h, P = .268) and lower aldosterone levels (4.6 ± 0.8 pg/mL vs 10.0 ± 3.0 pg/mL, P = .111). Estimated angiotensin-converting enzyme-2 (ACE2) activity was significantly lower in POTS patients than in controls (0.25 ± 0.02 vs 0.33 ± 0.03, P = .038).
CONCLUSION: Some patients with POTS have inappropriately high plasma Ang II levels, with low estimated ACE2 activity. We propose that these abnormalities in Ang regulation may play a key role in the pathophysiology of POTS in some patients.
Copyright © 2011 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21266211      PMCID: PMC3050076          DOI: 10.1016/j.hrthm.2010.11.009

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  34 in total

1.  Angiotensin-(1-7). A member of circulating angiotensin peptides.

Authors:  K Kohara; K B Brosnihan; M C Chappell; M C Khosla; C M Ferrario
Journal:  Hypertension       Date:  1991-02       Impact factor: 10.190

2.  Desensitization of AT1 receptor-mediated cellular responses requires long term receptor down-regulation in bovine adrenal glomerulosa cells.

Authors:  D E Richard; S A Laporte; S G Bernier; R Leduc; G Guillemette
Journal:  Endocrinology       Date:  1997-09       Impact factor: 4.736

3.  Reassessment of plasma angiotensins measurement: effects of protease inhibitors and sample handling procedures.

Authors:  K Kohara; Y Tabuchi; P Senanayake; K B Brosnihan; C M Ferrario
Journal:  Peptides       Date:  1991 Sep-Oct       Impact factor: 3.750

4.  Baroreflex control of muscle sympathetic nerve activity in postural orthostatic tachycardia syndrome.

Authors:  N Muenter Swift; N Charkoudian; R M Dotson; G A Suarez; P A Low
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-04-29       Impact factor: 4.733

5.  Angiotensin II down-regulates the vascular smooth muscle AT1 receptor by transcriptional and post-transcriptional mechanisms: evidence for homologous and heterologous regulation.

Authors:  B Lassègue; R W Alexander; G Nickenig; M Clark; T J Murphy; K K Griendling
Journal:  Mol Pharmacol       Date:  1995-10       Impact factor: 4.436

6.  The hemodynamic and neurohumoral phenotype of postural tachycardia syndrome.

Authors:  E M Garland; S R Raj; B K Black; P A Harris; D Robertson
Journal:  Neurology       Date:  2007-08-21       Impact factor: 9.910

7.  Increased expression of angiotensin peptides in the brain of transgenic hypertensive rats.

Authors:  P D Senanayake; A Moriguchi; H Kumagai; D Ganten; C M Ferrario; K B Brosnihan
Journal:  Peptides       Date:  1994       Impact factor: 3.750

8.  Angiotensin-(1-7) and nitric oxide interaction in renovascular hypertension.

Authors:  H Nakamoto; C M Ferrario; S B Fuller; D L Robaczewski; E Winicov; R H Dean
Journal:  Hypertension       Date:  1995-04       Impact factor: 10.190

9.  Abnormal adrenal responsiveness and angiotensin II dependency in high renin essential hypertension.

Authors:  R G Dluhy; S Z Bavli; F K Leung; H S Solomon; T J Moore; N K Hollenberg; G H Williams
Journal:  J Clin Invest       Date:  1979-11       Impact factor: 14.808

Review 10.  Pharmacologic modulation of ACE2 expression.

Authors:  María José Soler; Clara Barrios; Raymond Oliva; Daniel Batlle
Journal:  Curr Hypertens Rep       Date:  2008-10       Impact factor: 5.369

View more
  17 in total

Review 1.  Postural tachycardia syndrome (POTS).

Authors:  Satish R Raj
Journal:  Circulation       Date:  2013-06-11       Impact factor: 29.690

2.  Primary aldosteronism associated with a germline variant in CACNA1H.

Authors:  Kendra Wulczyn; Edward Perez-Reyes; Robert L Nussbaum; Meyeon Park
Journal:  BMJ Case Rep       Date:  2019-05-23

Review 3.  Confounders of vasovagal syncope: postural tachycardia syndrome.

Authors:  Victor C Nwazue; Satish R Raj
Journal:  Cardiol Clin       Date:  2013-02       Impact factor: 2.213

4.  Altered systemic hemodynamic and baroreflex response to angiotensin II in postural tachycardia syndrome.

Authors:  Hossam I Mustafa; Satish R Raj; André Diedrich; Bonnie K Black; Sachin Y Paranjape; William D Dupont; Gordon H Williams; Italo Biaggioni; David Robertson
Journal:  Circ Arrhythm Electrophysiol       Date:  2012-01-13

5.  Cutaneous constitutive nitric oxide synthase activation in postural tachycardia syndrome with splanchnic hyperemia.

Authors:  Julian M Stewart; Abhinav Nafday; Anthony J Ocon; Courtney Terilli; Marvin S Medow
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-06-03       Impact factor: 4.733

6.  Exercise training versus propranolol in the treatment of the postural orthostatic tachycardia syndrome.

Authors:  Qi Fu; Tiffany B Vangundy; Shigeki Shibata; Richard J Auchus; Gordon H Williams; Benjamin D Levine
Journal:  Hypertension       Date:  2011-06-20       Impact factor: 10.190

7.  Gastrointestinal symptoms in postural tachycardia syndrome: a systematic review.

Authors:  Shahram E Mehr; Adrian Barbul; Cyndya A Shibao
Journal:  Clin Auton Res       Date:  2018-03-16       Impact factor: 4.435

8.  Acute volume loading and exercise capacity in postural tachycardia syndrome.

Authors:  Rocío A Figueroa; Amy C Arnold; Victor C Nwazue; Luis E Okamoto; Sachin Y Paranjape; Bonnie K Black; Andre Diedrich; David Robertson; Italo Biaggioni; Satish R Raj; Alfredo Gamboa
Journal:  J Appl Physiol (1985)       Date:  2014-07-24

9.  Reversible postural orthostatic tachycardia syndrome.

Authors:  Aza Abdulla; Thirumagal Rajeevan
Journal:  World J Clin Cases       Date:  2015-07-16       Impact factor: 1.337

10.  Distinct neurohumoral biomarker profiles in children with hemodynamically defined orthostatic intolerance may predict treatment options.

Authors:  Ashley L Wagoner; Hossam A Shaltout; John E Fortunato; Debra I Diz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-11-25       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.